

Resource Summary Report

Generated by [RRID](#) on Sep 11, 2026

Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb

RRID:AB_2096270

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3777, RRID:AB_2096270

Antibody Information

URL: http://antibodyregistry.org/AB_2096270

Proper Citation: Cell Signaling Technology Cat# 3777, RRID:AB_2096270

Target Antigen: Phospho-EGF Receptor (Tyr1068)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IHC-P, IF-IC, F

Consolidation: AB_2277657

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb

Description: This recombinant monoclonal targets Phospho-EGF Receptor (Tyr1068)

Target Organism: rat, mouse, human

Clone ID: D7A5

Antibody ID: AB_2096270

Vendor: Cell Signaling Technology

Catalog Number: 3777

Alternative Catalog Numbers: 3777P, 3777S, 3777T

Record Creation Time: 20231110T073329+0000

Record Last Update: 20260829T161659+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 157 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Choi PH, et al. (2026) Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer. Cell reports, 45(7), 117559.

Li H, et al. (2026) PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation. Oncogene, 45(4), 577.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. Cancer research, 86(6), 1467.

Asmanidou S, et al. (2026) BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. Cell death & disease, 17(1), 187.

Thielen N, et al. (2026) High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. NPJ precision oncology, 10(1).

Ge X, et al. (2026) PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. Cancer research, 86(15), 3819.

Ma H, et al. (2026) BCAA metabolism promotes lung cancer tumorigenesis by enhancing cholesterol biosynthesis. Cell reports, 45(7), 117641.

Wang Y, et al. (2026) A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. *Cellular oncology (Dordrecht, Netherlands)*, 49(1), 31.

An K, et al. (2026) Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy. *Neoplasia (New York, N.Y.)*, 79, 101328.

Osorio-Vasquez V, et al. (2026) Patient-derived organoids reveal ductal dysfunction and CFTR-modulator responses in chronic pancreatitis. *Cell stem cell*.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

Carta L, et al. (2026) Identification of Small-Molecule Inhibitors that Block the GTP-Binding Pocket of K-Ras and Other Members of the Ras Superfamily of Small GTPases. *Molecular cancer therapeutics*, 25(1), 84.

Lin X, et al. (2026) UBE2M-mediated EGFR neddylation drives keratinocyte proliferation in psoriasis. *iScience*, 29(5), 115784.

Yoshichika R, et al. (2026) Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer. *Cancer immunology, immunotherapy : CII*, 75(4).

Liao J, et al. (2026) Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. *Cancer cell*, 44(7), 1401.

Grimont A, et al. (2026) Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis. *Developmental cell*.

Karunaraj P, et al. (2026) A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance. *Nature communications*, 17(1).

Ojeda-Juarez D, et al. (2026) PrPC-facilitated cell signaling activates phospholipase C γ 1 and triggers an Arc/Arg3.1 response in mouse and iPSC-derived human neurons. *Stem cell reports*, 21(6), 102924.

Zheng J, et al. (2025) Dapk2 dysfunction leads to Mic60 lactylation and mitochondrial metabolic reprogramming, promoting lung cancer EGFR-TKI resistance and metastasis. *Developmental cell*.

Karunaraj P, et al. (2025) A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance. *Research square*.